Jupiter Asset Management Ltd. Invests $1.95 Million in Twist Bioscience Corporation $TWST

Jupiter Asset Management Ltd. acquired a new stake in Twist Bioscience Corporation (NASDAQ:TWST) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 53,026 shares of the company’s stock, valued at approximately $1,951,000.

Several other hedge funds also recently bought and sold shares of TWST. Envestnet Asset Management Inc. increased its holdings in Twist Bioscience by 27.3% during the 1st quarter. Envestnet Asset Management Inc. now owns 70,279 shares of the company’s stock worth $2,759,000 after acquiring an additional 15,085 shares during the period. Xponance Inc. increased its holdings in shares of Twist Bioscience by 22.0% in the first quarter. Xponance Inc. now owns 5,953 shares of the company’s stock worth $234,000 after purchasing an additional 1,072 shares during the period. New York State Common Retirement Fund raised its position in shares of Twist Bioscience by 2.4% in the first quarter. New York State Common Retirement Fund now owns 452,750 shares of the company’s stock worth $17,775,000 after buying an additional 10,761 shares in the last quarter. CWM LLC boosted its stake in Twist Bioscience by 161.4% during the first quarter. CWM LLC now owns 16,272 shares of the company’s stock valued at $639,000 after buying an additional 10,048 shares during the period. Finally, Allianz Asset Management GmbH increased its stake in Twist Bioscience by 6.3% in the 1st quarter. Allianz Asset Management GmbH now owns 17,000 shares of the company’s stock worth $667,000 after acquiring an additional 1,000 shares during the last quarter.

Twist Bioscience Price Performance

Shares of TWST opened at $29.90 on Friday. The company has a market capitalization of $1.80 billion, a P/E ratio of -20.62 and a beta of 2.43. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a twelve month low of $24.07 and a twelve month high of $55.33. The firm has a 50 day moving average of $29.72 and a 200 day moving average of $31.49.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TWST. Stephens started coverage on Twist Bioscience in a research report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target for the company. Evercore ISI cut their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Barclays lowered their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, October 2nd. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $47.80.

Insider Activity

In other news, CFO Adam Laponis sold 5,517 shares of Twist Bioscience stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total value of $173,454.48. Following the completion of the sale, the chief financial officer directly owned 111,008 shares in the company, valued at $3,490,091.52. The trade was a 4.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Robert F. Werner sold 1,016 shares of Twist Bioscience stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $31,943.04. Following the completion of the sale, the chief accounting officer directly owned 51,030 shares of the company’s stock, valued at approximately $1,604,383.20. This trade represents a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 122,865 shares of company stock worth $3,879,926. 3.01% of the stock is owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.